The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
hDOT1L Links Histone Methylation to Leukemogenesis
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., et al. (1999) · Science · doi:10.1126/science.286.5439.531 · Cited by 11,516
The language of covalent histone modifications
Strahl, B. D., & Allis, C. D. (2000) · Nature · doi:10.1038/47412 · Cited by 8,679
The polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717
Active Genes Are Tri-Methylated at K4 of Histone H3
Santos-Rosa, H., Schneider, R., Bannister, A. J., Sherriff, J., Bernstein, B. E., Emre, N. C. T., Schreiber, S. L., Mellor, J., & Kouzarides, T. (2002) · Nature · doi:10.1038/nature01080 · Cited by 2,138
Kleer, C. G., Cao, Q., Varambally, S., Shen, R., Ota, I., Tomlins, S. A., Ghosh, D., Sewalt, R. G. A. B., Otte, A. P., Hayes, D. F., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1933744100 · Cited by 1,649
Zhang, Y., & Reinberg, D. (2001) · Genes & Development · doi:10.1101/gad.927301 · Cited by 1,530
Self-citationEZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer.
Bracken, A. P., Pasini, D., Capra, M., Prosperini, E., Colli, E., & Helin, K. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg542 · Cited by 1,196
MLL Targets SET Domain Methyltransferase Activity to Hox Gene Promoters
Milne, T. A., Briggs, S. D., Brock, H. W., Martin, M. E., Gibbs, D., Allis, C. D., & Hess, J. L. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00741-4 · Cited by 1,053
Methylation of H3-Lysine 79 Is Mediated by a New Family of HMTases without a SET Domain
Feng, Q., Wang, H., Ng, H. H., Erdjument-Bromage, H., Tempst, P., Struhl, K., & Zhang, Y. (2002) · Current Biology · doi:10.1016/s0960-9822(02)00901-6 · Cited by 865
Self-citationDot1p Modulates Silencing in Yeast by Methylation of the Nucleosome Core
van Leeuwen, F., Gafken, P. R., & Gottschling, D. E. (2002) · Cell · doi:10.1016/s0092-8674(02)00759-6 · Cited by 853
Cited by
High-Resolution Profiling of Histone Methylations in the Human Genome
Barski, A., Cuddapah, S., Cui, K., Roh, T.-Y., Schones, D. E., Wang, Z., Wei, G., Chepelev, I., & Zhao, K. (2007) · Cell · doi:10.1016/j.cell.2007.05.009 · Cited by 6,845
“H3K79me3 does not show a correlation with either active or silent genes in yeast (Pokholok et al., 2005), while H3K79me2 was linked to active transcription in Drosophila (Schubeler et al., 2004) and in humans (Okada et al., 2005).”
BackgroundA decade of exploring the cancer epigenome—biological and translational implications
Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871
The diverse functions of histone lysine methylation
Martin, C., & Zhang, Y. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1761 · Cited by 2,057
Self-citationFTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N 6 -Methyladenosine RNA Demethylase
Li, Z., Weng, H., Su, R., Weng, X., Zuo, Z., Li, C., Huang, H., Nachtergaele, S., Dong, L., Hu, C., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2016.11.017 · Cited by 1,508
Self-citationEpigenetic protein families: a new frontier for drug discovery
Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., & Schapira, M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3674 · Cited by 1,327
Histone Lysine Methylation Dynamics: Establishment, Regulation, and Biological Impact
Black, J. C., Van Rechem, C., & Whetstine, J. R. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.11.006 · Cited by 1,308
Writing, erasing and reading histone lysine methylations
Hyun, K., Jeon, J., Park, K., & Kim, J. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.11 · Cited by 1,250
MLL translocations, histone modifications and leukaemia stem-cell development
Krivtsov, A. V., & Armstrong, S. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2253 · Cited by 1,249
Shilatifard, A. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.103004.142422 · Cited by 1,103
Covalent histone modifications — miswritten, misinterpreted and mis-erased in human cancers
Chi, P., Allis, C. D., & Wang, G. G. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2876 · Cited by 1,099
Reversal of Histone Lysine Trimethylation by the JMJD2 Family of Histone Demethylases
Whetstine, J. R., Nottke, A., Lan, F., Huarte, M., Smolikov, S., Chen, Z., Spooner, E., Li, E., Zhang, G., Colaiacovo, M., et al. (2006) · Cell · doi:10.1016/j.cell.2006.03.028 · Cited by 1,040
Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor
Daigle, S. R., Olhava, E. J., Therkelsen, C. A., Majer, C. R., Sneeringer, C. J., Song, J., Johnston, L. D., Scott, M. P., Smith, J. J., Xiao, Y., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.009 · Cited by 923
Lateral Thinking: How Histone Modifications Regulate Gene Expression
Lawrence, M., Daujat, S., & Schneider, R. (2016) · Trends in Genetics · doi:10.1016/j.tig.2015.10.007 · Cited by 908
MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L
Bernt, K. M., Zhu, N., Sinha, A. U., Vempati, S., Faber, J., Krivtsov, A. V., Feng, Z., Punt, N., Daigle, A., Bullinger, L., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.010 · Cited by 870
Yamane, K., Toumazou, C., Tsukada, Y.-I., Erdjument-Bromage, H., Tempst, P., Wong, J., & Zhang, Y. (2006) · Cell · doi:10.1016/j.cell.2006.03.027 · Cited by 837
Self-citationPotent inhibition of DOT1L as treatment of MLL-fusion leukemia
Daigle, S. R., Olhava, E. J., Therkelsen, C. A., Basavapathruni, A., Jin, L., Boriack-Sjodin, P. A., Allain, C. J., Klaus, C. R., Raimondi, A., Scott, M. P., et al. (2013) · Blood · doi:10.1182/blood-2013-04-497644 · Cited by 722
Dynamic Regulation of Histone Lysine Methylation by Demethylases
Shi, Y., & Whetstine, J. R. (2007) · Molecular Cell · doi:10.1016/j.molcel.2006.12.010 · Cited by 707
Yokoyama, A., Somervaille, T. C. P., Smith, K. S., Rozenblatt-Rosen, O., Meyerson, M., & Cleary, M. L. (2005) · Cell · doi:10.1016/j.cell.2005.09.025 · Cited by 688
The MLL recombinome of acute leukemias in 2017
Meyer, C., Burmeister, T., Gröger, D., Tsaur, G., Fechina, L., Renneville, A., Sutton, R., Venn, N. C., Emerenciano, M., Pombo-de-Oliveira, M. S., et al. (2018) · Leukemia · doi:10.1038/leu.2017.213 · Cited by 676
Hijacked in cancer: the KMT2 (MLL) family of methyltransferases
Rao, R. C., & Dou, Y. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3929 · Cited by 669
Chromatin-modifying enzymes as modulators of reprogramming
Onder, T. T., Kara, N., Cherry, A., Sinha, A. U., Zhu, N., Bernt, K. M., Cahan, P., Mancarci, B. O., Unternaehrer, J., Gupta, P. B., et al. (2012) · Nature · doi:10.1038/nature10953 · Cited by 634
Aberrant Epigenetic Landscape in Cancer: How Cellular Identity Goes Awry
Berdasco, M., & Esteller, M. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.10.005 · Cited by 618
The diverse functions of Dot1 and H3K79 methylation
Nguyen, A. T., & Zhang, Y. (2011) · Genes & Development · doi:10.1101/gad.2057811 · Cited by 597
Self-citationLin, C., Smith, E. R., Takahashi, H., Lai, K. C., Martin-Brown, S., Florens, L., Washburn, M. P., Conaway, J. W., Conaway, R. C., & Shilatifard, A. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.01.026 · Cited by 573
H3K79 Methylation Profiles Define Murine and Human MLL-AF4 Leukemias
Krivtsov, A. V., Feng, Z., Lemieux, M. E., Faber, J., Vempati, S., Sinha, A. U., Xia, X., Jesneck, J., Bracken, A. P., Silverman, L. B., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.10.001 · Cited by 550
Understanding the relationship between DNA methylation and histone lysine methylation
Rose, N. R., & Klose, R. J. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.02.007 · Cited by 542
Monoubiquitination of Human Histone H2B: The Factors Involved and Their Roles in HOX Gene Regulation
Zhu, B., Zheng, Y., Pham, A.-D., Mandal, S. S., Erdjument-Bromage, H., Tempst, P., & Reinberg, D. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.09.025 · Cited by 532
RAR and RXR modulation in cancer and metabolic disease
Altucci, L., Leibowitz, M. D., Ogilvie, K. M., de Lera, A. R., & Gronemeyer, H. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2397 · Cited by 517
Steger, D. J., Lefterova, M. I., Ying, L., Stonestrom, A. J., Schupp, M., Zhuo, D., Vakoc, A. L., Kim, J.-E., Chen, J., Lazar, M. A., et al. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.02076-07 · Cited by 497
Yamane, K., Tateishi, K., Klose, R. J., Fang, J., Fabrizio, L. A., Erdjument-Bromage, H., Taylor-Papadimitriou, J., Tempst, P., & Zhang, Y. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.03.001 · Cited by 493
Self-citationThe MLL recombinome of acute leukemias in 2013
Meyer, C., Hofmann, J., Burmeister, T., Gröger, D., Park, T. S., Emerenciano, M., Pombo de Oliveira, M., Renneville, A., Villarese, P., Macintyre, E., et al. (2013) · Leukemia · doi:10.1038/leu.2013.135 · Cited by 491
Stein, E. M., Garcia-Manero, G., Rizzieri, D. A., Tibes, R., Berdeja, J. G., Savona, M. R., Jongen-Lavrenic, M., Altman, J. K., Thomson, B., Blakemore, S. J., et al. (2018) · Blood · doi:10.1182/blood-2017-12-818948 · Cited by 461
Protein methyltransferases as a target class for drug discovery
Copeland, R. A., Solomon, M. E., & Richon, V. M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2974 · Cited by 460
Plass, C., Pfister, S. M., Lindroth, A. M., Bogatyrova, O., Claus, R., & Lichter, P. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3554 · Cited by 453
Krivtsov, A. V., Evans, K., Gadrey, J. Y., Eschle, B. K., Hatton, C., Uckelmann, H. J., Ross, K. N., Perner, F., Olsen, S. N., Pritchard, T., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.11.001 · Cited by 447
Histone Crosstalk between H2B Monoubiquitination and H3 Methylation Mediated by COMPASS
Lee, J.-S., Shukla, A., Schneider, J., Swanson, S. K., Washburn, M. P., Florens, L., Bhaumik, S. R., & Shilatifard, A. (2007) · Cell · doi:10.1016/j.cell.2007.09.046 · Cited by 438
Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger
Wang, G. G., Song, J., Wang, Z., Dormann, H. L., Casadio, F., Li, H., Luo, J.-L., Patel, D. J., & Allis, C. D. (2009) · Nature · doi:10.1038/nature08036 · Cited by 438
NUP98–NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis
Wang, G. G., Cai, L., Pasillas, M. P., & Kamps, M. P. (2007) · Nature Cell Biology · doi:10.1038/ncb1608 · Cited by 437
Chromatin proteins and modifications as drug targets
Helin, K., & Dhanak, D. (2013) · Nature · doi:10.1038/nature12751 · Cited by 427
Epigenetics in cancer stem cells
Toh, T. B., Lim, J. J., & Chow, E. K.-H. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0596-9 · Cited by 422
Chromatin remodeling and cancer, part I: covalent histone modifications
Wang, G. G., Allis, C. D., & Chi, P. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.07.003 · Cited by 418
New insights to the MLL recombinome of acute leukemias
Meyer, C., Kowarz, E., Hofmann, J., Renneville, A., Zuna, J., Trka, J., Ben Abdelali, R., Macintyre, E., De Braekeleer, E., De Braekeleer, M., et al. (2009) · Leukemia · doi:10.1038/leu.2009.33 · Cited by 407
Profile of Histone Lysine Methylation across Transcribed Mammalian Chromatin
Vakoc, C. R., Sachdeva, M. M., Wang, H., & Blobel, G. A. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.01529-06 · Cited by 406
MLL-Rearranged Leukemias—An Update on Science and Clinical Approaches
Winters, A. C., & Bernt, K. M. (2017) · Frontiers in Pediatrics · doi:10.3389/fped.2017.00004 · Cited by 405
A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification
Mueller, D., Bach, C., Zeisig, D., Garcia-Cuellar, M.-P., Monroe, S., Sreekumar, A., Zhou, R., Nesvizhskii, A., Chinnaiyan, A., Hess, J. L., et al. (2007) · Blood · doi:10.1182/blood-2007-05-090514 · Cited by 397
Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy
Morera, L., Lübbert, M., & Jung, M. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0223-4 · Cited by 395
Jones, B., Su, H., Bhat, A., Lei, H., Bajko, J., Hevi, S., Baltus, G. A., Kadam, S., Zhai, H., Valdez, R., et al. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.1000190 · Cited by 383
Self-citationSobhian, B., Laguette, N., Yatim, A., Nakamura, M., Levy, Y., Kiernan, R., & Benkirane, M. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.04.012 · Cited by 381
Critical roles of non-histone protein lysine methylation in human tumorigenesis
Hamamoto, R., Saloura, V., & Nakamura, Y. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3884 · Cited by 376
Yokoyama, A., Lin, M., Naresh, A., Kitabayashi, I., & Cleary, M. L. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.040 · Cited by 374
Upregulation of miR-196a and HOTAIR Drive Malignant Character in Gastrointestinal Stromal Tumors
Niinuma, T., Suzuki, H., Nojima, M., Nosho, K., Yamamoto, H., Takamaru, H., Yamamoto, E., Maruyama, R., Nobuoka, T., Miyazaki, Y., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1803 · Cited by 354
The Pathogenesis of Mixed-Lineage Leukemia
Muntean, A. G., & Hess, J. L. (2012) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-132434 · Cited by 344
Histone lysine methylation and demethylation pathways in cancer
Varier, R. A., & Timmers, H. T. M. (2011) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.10.002 · Cited by 334
The Role of DNA Methylation and Histone Modifications in Transcriptional Regulation in Humans
Miller, J. L., & Grant, P. A. (2013) · Subcellular Biochemistry · doi:10.1007/978-94-007-4525-4_13 · Cited by 323
The molecular biology of mixed lineage leukemia
Slany, R. K. (2009) · Haematologica · doi:10.3324/haematol.2008.002436 · Cited by 321
Transcription control by the ENL YEATS domain in acute leukaemia
Erb, M. A., Scott, T. G., Li, B. E., Xie, H., Paulk, J., Seo, H.-S., Souza, A., Roberts, J. M., Dastjerdi, S., Buckley, D. L., et al. (2017) · Nature · doi:10.1038/nature21688 · Cited by 318
Linking H3K79 trimethylation to Wnt signaling through a novel Dot1-containing complex (DotCom)
Mohan, M., Herz, H.-M., Takahashi, Y.-H., Lin, C., Lai, K. C., Zhang, Y., Washburn, M. P., Florens, L., & Shilatifard, A. (2010) · Genes & Development · doi:10.1101/gad.1898410 · Cited by 313
Self-citationBitoun, E., Oliver, P. L., & Davies, K. E. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddl444 · Cited by 312
Leukaemogenesis: more than mutant genes
Chen, J., Odenike, O., & Rowley, J. D. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2765 · Cited by 311
Histone methyltransferases in cancer
Albert, M., & Helin, K. (2010) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2009.10.007 · Cited by 306
Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance
Wilting, R. H., & Dannenberg, J.-H. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.01.008 · Cited by 303
Targeting MLL1 H3K4 Methyltransferase Activity in Mixed-Lineage Leukemia
Cao, F., Townsend, E. C., Karatas, H., Xu, J., Li, L., Lee, S., Liu, L., Chen, Y., Ouillette, P., Zhu, J., et al. (2014) · Molecular Cell · doi:10.1016/j.molcel.2013.12.001 · Cited by 301
Menin: a scaffold protein that controls gene expression and cell signaling
Matkar, S., Thiel, A., & Hua, X. (2013) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2013.05.005 · Cited by 292
Protein arginine-methyltransferase-dependent oncogenesis
Cheung, N., Chan, L. C., Thompson, A., Cleary, M. L., & So, C. W. E. (2007) · Nature Cell Biology · doi:10.1038/ncb1642 · Cited by 291
Marked for death: Targeting epigenetic changes in cancer
Pfister, S. X., & Ashworth, A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.256 · Cited by 288
Veloso, A., Kirkconnell, K. S., Magnuson, B., Biewen, B., Paulsen, M. T., Wilson, T. E., & Ljungman, M. (2014) · Genome Research · doi:10.1101/gr.171405.113 · Cited by 281
Zuber, J., Rappaport, A. R., Luo, W., Wang, E., Chen, C., Vaseva, A. V., Shi, J., Weissmueller, S., Fellman, C., Taylor, M. J., et al. (2011) · Genes & Development · doi:10.1101/gad.17269211 · Cited by 279
DOT1L, the H3K79 methyltransferase, is required for MLL-AF9–mediated leukemogenesis
Nguyen, A. T., Taranova, O., He, J., & Zhang, Y. (2011) · Blood · doi:10.1182/blood-2011-02-334359 · Cited by 275
Self-citationThe MLL recombinome of acute leukemias
Meyer, C., Schneider, B., Jakob, S., Strehl, S., Attarbaschi, A., Schnittger, S., Schoch, C., Jansen, M. W. J. C., van Dongen, J. J. M., den Boer, M. L., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404150 · Cited by 271
β-Catenin Mediates the Establishment and Drug Resistance of MLL Leukemic Stem Cells
Yeung, J., Esposito, M. T., Gandillet, A., Zeisig, B. B., Griessinger, E., Bonnet, D., & So, C. W. E. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.032 · Cited by 270
Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia
Guenther, M. G., Lawton, L. N., Rozovskaia, T., Frampton, G. M., Levine, S. S., Volkert, T. L., Croce, C. M., Nakamura, T., Canaani, E., & Young, R. A. (2008) · Genes & Development · doi:10.1101/gad.1741408 · Cited by 270
Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential
Wong, P., Iwasaki, M., Somervaille, T. C. P., So, C. W. E., & Cleary, M. L. (2007) · Genes & Development · doi:10.1101/gad.1602107 · Cited by 266
Activating hotspot L205R mutation in PRKACA and adrenal Cushing’s syndrome
Cao, Y., He, M., Gao, Z., Peng, Y., Li, Y., Li, L., Zhou, W., Li, X., Zhong, X., Lei, Y., et al. (2014) · Science · doi:10.1126/science.1249480 · Cited by 232
Self-citationCho, M.-H., Park, J.-H., Choi, H.-J., Park, M.-K., Won, H.-Y., Park, Y.-J., Lee, C. H., Oh, S.-H., Song, Y.-S., Kim, H. S., et al. (2015) · Nature Communications · doi:10.1038/ncomms8821 · Cited by 211
DOT1L and H3K79 Methylation in Transcription and Genomic Stability
Wood, K., Tellier, M., & Murphy, S. (2018) · Biomolecules · doi:10.3390/biom8010011 · Cited by 209
“For example, an MLL-AF10 fusion promotes DOT1L-mediated methylation of H3K79 at the HoxA9 promoter, which contributes to upregulation of expression of HoxA9 in acute myeloid leukemia.”
BackgroundInfluentialStructural Basis of Substrate Methylation and Inhibition of SMYD2
Ferguson, A. D., Larsen, N. A., Howard, T., Pollard, H., Green, I., Grande, C., Cheung, T., Garcia-Arenas, R., Cowen, S., Wu, J., et al. (2011) · Structure · doi:10.1016/j.str.2011.06.011 · Cited by 203
“Indeed, many protein lysine methyltransferases act as classical oncogenes that are capable of driving cellular transformation (Okada et al., 2005; Karanikolas et al., 2009).”
BackgroundGenome-Wide Analysis of KAP1 Binding Suggests Autoregulation of KRAB-ZNFs
O'Geen, H., Squazzo, S. L., Iyengar, S., Blahnik, K., Rinn, J. L., Chang, H. Y., Green, R., & Farnham, P. J. (2007) · PLoS Genetics · doi:10.1371/journal.pgen.0030089 · Cited by 178
Role of Epigenetics in Inflammation-Associated diseases
Shanmugam, M. K., & Sethi, G. (2013) · Subcellular Biochemistry · doi:10.1007/978-94-007-4525-4_27 · Cited by 141
The emerging roles of DOT1L in leukemia and normal development
McLean, C. M., Karemaker, I. D., & van Leeuwen, F. (2014) · Leukemia · doi:10.1038/leu.2014.169 · Cited by 118
DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia
Rau, R. E., Rodriguez, B. A., Luo, M., Jeong, M., Rosen, A., Rogers, J. H., Campbell, C. T., Daigle, S. R., Deng, L., Song, Y., et al. (2016) · Blood · doi:10.1182/blood-2015-11-684225 · Cited by 122
Histone H2B ubiquitin ligase RNF20 is required for MLL -rearranged leukemia
Wang, E., Kawaoka, S., Yu, M., Shi, J., Ni, T., Yang, W., Zhu, J., Roeder, R. G., & Vakoc, C. R. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1301045110 · Cited by 121
Wakeman, T. P., Wang, Q., Feng, J., & Wang, X. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.50 · Cited by 113
Shukla, A., Chaurasia, P., & Bhaumik, S. R. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8605-1 · Cited by 98
Lin, Y.-H., Kakadia, P. M., Chen, Y., Li, Y.-Q., Deshpande, A. J., Buske, C., Zhang, K.-L., Zhang, Y., Xu, G.-L., & Bohlander, S. K. (2009) · Blood · doi:10.1182/blood-2009-03-209395 · Cited by 64
Self-citationMLL leukemia induction by genome editing of human CD34+ hematopoietic cells
Buechele, C., Breese, E. H., Schneidawind, D., Lin, C.-H., Jeong, J., Duque-Afonso, J., Wong, S. H. K., Smith, K. S., Negrin, R. S., Porteus, M., et al. (2015) · Blood · doi:10.1182/blood-2015-05-646398 · Cited by 60
“DOT1L catalyzes the methylation of H3K79, a chromatin modification that leads to enhanced expression of leukemogenic genes, including HOXA9 and MEIS1 in MLLrearranged leukemias.(34-44) Small-molecule inhibitors of DOT1L have been developed and are currently undergoing phase I clinical trials.”
BackgroundPU.1 is essential for MLL leukemia partially via crosstalk with the MEIS/HOX pathway
Zhou, J., Wu, J., Li, B., Liu, D., Yu, J., Yan, X., Zheng, S., Wang, J., Zhang, L., Zhang, L., et al. (2014) · Leukemia · doi:10.1038/leu.2013.384 · Cited by 53
Self-citationHemming, M. L., Benson, M. R., Loycano, M. A., Anderson, J. A., Andersen, J. L., Taddei, M. L., Krivtsov, A. V., Aubrey, B. J., Cutler, J. A., Hatton, C., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0646 · Cited by 39
A distinct core regulatory module enforces oncogene expression in KMT2A-rearranged leukemia
(2022) · doi:10.1101/gad.349284.121 · Cited by 31
Metadata
- Authors
- Okada, Y., Feng, Q., Lin, Y., Jiang, Q., Li, Y., Coffield, V. M., Su, L., Xu, G., & Zhang, Y.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2005-04
- Volume
- 121
- Issue
- 2
- Pages
- 167-178
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W2048613921
- Cited by
- 804
- References
- 33
- FWCI
- 18.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.